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Introduction
The γ-herpesvirus KSHV, also called HHV-8, is the etiological 
agent of Kaposi’s sarcoma (KS) (1), multicentric Castleman’s dis-
ease (2), and primary effusion lymphoma (PEL) (3). KS, the most 
common malignancy in AIDS patients, is a tumor of endothe-
lial origin, while PEL is a rare non-Hodgkin B cell lymphoma that 
commonly manifests as lymphomatous effusions. Combined anti-
retroviral therapy has been shown to be effective in some cases of 
KS, as are other noncurative approaches such as radiation, surgery, 
and chemotherapy. However, PEL itself remains by and large a 
highly aggressive and intractable disease, with rapid progression 
to death. Therefore, the need for specific and effective therapeu-
tics for diseases involving KSHV is pressing, albeit challenging 
because of the latent nature of the virus.
Two broad approaches can be envisioned to identify new strat-
egies for the treatment of virus-associated malignancies to target 
specific vulnerabilities conferred by viral infection. The first one 
is to use existing agents that target pathways that are activated by 
the virus and are essential for tumor cell survival. The advantage 
of this strategy is the availability of compounds previously tested 
for other diseases and in clinical use, with documented pharmaco-
logical properties. We and other groups have studied the effective-
ness of such commercially available or clinically established path-
way inhibitors, such as the NF-κB inhibitor Bay11-7082 and the 
Hsp90 inhibitor PU-H71, in PEL cell lines (4–6). However, none of 
these have been completely effective in mouse models or involved 
the use of compounds that are already past early phases of clinical 
trials. A second approach is to identify specific inhibitors of viral 
proteins, which provides the unique opportunity for very specific 
and potentially nontoxic therapy. One possible candidate viral 
oncogene is vFLIP, a viral latent protein encoded by KSHV and 
expressed in all infected tumor cells. vFLIP is essential for PEL cell 
survival as demonstrated by RNAi (7); this effect is mediated by 
binding of vFLIP to IKKγ and activation of the downstream NF-κB 
pathway (8, 9). We sought to exploit the dependence of PEL cells 
on vFLIP-induced NF-κB signaling by conducting a high-through-
put screen using an NF-κB reporter cell line, and searching for 
molecules that inhibit NF-κB in PEL but not in KSHV– cell lines.
We successfully identified a novel inhibitor, 6-ethylthioino-
sine (6-ETI), a compound that is highly selective for PEL cell 
lines in vitro and highly efficacious in vivo. Unexpectedly, this 
compound did not decrease levels of vFLIP or other viral pro-
teins, and toxicity at low concentrations occurred irrespective of 
vFLIP-induced NF-κB signaling suppression. Unbiased analysis 
of mechanisms of resistance using a genomic approach revealed 
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As a next step to determine 
specificity, we developed a 
secondary assay, wherein the 
single reporter cell line was 
lentivirally transduced with a 
constitutive renilla luciferase 
construct. The transduced cell 
line was subcloned to gener-
ate the double reporter cell line 
BC3NFRen-luc#3. We tested 
the 50 hit compounds using 
the double reporter cell line, 
as well as an additional control 
cell line, U251-pGL3, derived 
from a glioma cell line, U251, 
which expresses firefly lucif-
erase constitutively under the 
control of the SV40 promoter 
(provided by G. Mellilo, Nation-
al Cancer Institute). Screening 
the double reporter and control 
cell line led to the identification 
of 3 hit compounds that were 
found to possess specific anti–
NF-κB activity against PEL cells 
(Supplemental Table 2). We 
performed detailed chemoin-
formatic analysis on these hit 
compounds and identified 66 
additional analogs in the NIH 
compound repository, which 
were screened by the double 
reporter assay for structure-activity relationship. Results from this 
analysis informed further analog identification; 39 additional ana-
logs were screened by the double reporter assay in this second-tier 
analysis. Rescreening validated 3 analogs of 2 of the parent com-
pounds as additional hits for NF-κB inhibition in PEL cells (Sup-
plemental Table 2).
Selection of 6-ETI. We examined the 6 hit compounds obtained 
at the end of high-throughput screening (Supplemental Table 
2) for inhibition of the NF-κB pathway in parental BC3 cells. 
Supplemental Figure 1A shows that the compound NSC39368 
effectively inhibited active heterodimer p65/p50 binding to the 
NF-κB response element by EMSA. This inhibition occurred in 
the BC3 PEL cell line, but not in a control lymphoblastoid cell line 
(LCL9001) containing EBV (Figure 1A). This result enabled us to 
identify NSC39368 or 6-ethylthioinosine, a nucleoside analog, 
hereafter referred to as 6-ETI, as the most promising compound 
for further investigation.
NF-κB reporter assays performed on BC3NFRen-luc#3 cells 
confirmed that 6-ETI inhibited NF-κB activity in this cell line as 
early as 6 hours after treatment (Supplemental Figure 1B). 6-ETI 
treatment in BC3 cells was found to decrease levels of active 
subunit p65 in the nucleus, while leaving inactive subunit p50 
unchanged (Supplemental Figure 1C), and it also decreased levels 
of IL-6, an NF-κB–dependent gene in PEL cells (Supplemental Fig-
ure 1D). Other components of classical NF-κB signaling, including 
an unpredicted dependency of 6-ETI on phosphorylation by 
endogenous adenosine kinase (ADK) for its exquisite selectiv-
ity. Furthermore, ADK overexpression was found to serve as a 
new biomarker for 6-ETI sensitivity in other related tumors, and 
in particular in multiple myeloma, expanding the scope of this 
inhibitor as an effective preclinical agent. Our results demon-
strate the use of unbiased genomic analysis to identify mecha-
nisms of resistance and of action and to enable target identifica-
tion of novel lead compounds.
Results
Development of a high-throughput screening assay using a PEL- 
specific NF-κB reporter cell line. The PEL cell line BC3 was previ-
ously modified through transduction of NF-κB–firefly lucifer-
ase plasmid, followed by selection and subcloning, to yield the 
BC3NFκB-luc#6 single reporter cell line (6). We screened the 
NIH Training Set (230 compounds) using this cell line, and deter-
mined optimal assay conditions for high-throughput screening 
(Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI83936DS1). The 
established cell-based luciferase reporter assay was used to 
screen the NIH Diversity Set (1,981 compounds) at 5 μM, yielding 
60 primary hits that demonstrated at least 50% NF-κB–luciferase 
inhibition, for an initial hit rate of 3%. Retesting of these hit com-
pounds determined 50 to be genuine.
Figure 1. Selection of 6-ETI. (A) BC3 (KSHV+) and LCL9001 (KSHV–) cells were treated for 24 hours with selected 
doses of NSC39368 (6-ETI), followed by nuclear extraction and EMSA to determine binding to an NF-κB response 
element. Control lanes include no compound, competition with cold probe, untreated, and DMSO-treated samples. 
Experiment was performed 3 separate times. A representative blot is shown. (B) A panel of KSHV+ (black bars) and 
KSHV– (gray bars) cell lines was plated at 1 × 105 cells/ml in RPMI with 20% FBS with increasing concentrations of 
6-ETI, followed by analysis for ATP content by CellTiter-Glo assay at 48 hours. LC50s were determined by online EC50 
software. Results are mean ± SEM of at least 3 independent experiments. (C) BC3 and IBL1 cells plated at 1 × 105 
cells/ml in RPMI with 20% FBS at a range of concentrations of 6-ETI were examined for cell death by trypan blue 
staining–aided cell counts at 48 hours after treatment. Results plotted are mean ± SEM of at least 3 independent 
experiments. (D) BC3 and IBL1 cells plated at 2 × 105 cells/ml in RPMI with 20% FBS were treated with DMSO or 
500 nM or 5 μM 6-ETI for 48 hours and analyzed by flow cytometry for cell death after staining with annexin V and 
7-aminoactinomycin D. Results are the average of at least 2 independent experiments (mean ± SEM).
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striking correlation of effectiveness with KSHV infection status of 
the cell. Cell lines that were KSHV+ had LC50s in the mid-nanomolar 
range, varying from approximately 30 to 435 nM, while all KSHV– 
cell lines tested, regardless of tumor type, EBV infection status, or 
NF-κB dependence, exhibited LC50s in the micromolar (10–80 μM) 
range, showing an average fold difference in sensitivity of approxi-
mately 275 (P = 0.0001, unpaired t test). To ensure concordance 
between ATP levels and cell death, viability for a selected PEL and 
non-PEL cell line was also assessed by trypan blue exclusion, yield-
ing LC50s of 74 nM and 134 μM, respectively (Figure 1C). The 6-ETI–
treated PEL cell line also had a higher proportion of dead cells as 
determined by annexin V/7-aminoactinomycin D staining (Figure 
1D). Notably, the 6-ETI doses that had been found to be effective in 
inhibiting NF-κB in PELs were in the range of 10–50 μM, while cell 
viability was impacted at nanomolar doses, indicating that NF-κB 
inhibition was a secondary effect of this compound and not the pri-
mary mechanism involved in cell death.
IKKα, IKKβ, and IκBα, were not consistently affected by 6-ETI 
treatment (Supplemental Figure 1D). Thus, like other inhibitors 
of NF-κB (10, 11), 6-ETI inhibited p65 nuclear accumulation, but 
the mechanism for this selective inhibition of p65 nuclear localiza-
tion in PEL was not evident from immunoblot analysis of known 
upstream regulators of this process.
6-ETI specifically inhibits PEL cell viability. To assess toxicity and 
confirm selectivity toward PEL, we examined 6-ETI for its effective-
ness against a panel of cell lines, including KSHV+ PEL, KSHV+EBV+ 
PEL, EBV+ immunoblastic lymphomas (IBL1), EBV+ lymphoblas-
toid cell lines (LCL), EBV– Hodgkin’s lymphoma (HL) cell lines, 
EBV+ and EBV– Burkitt’s lymphoma (BL) cell lines, virus-negative 
diffuse large B cell lymphoma (DLBCL) cell lines, several of which 
are known to be NF-κB–dependent, and normal peripheral blood 
leukocytes. We used an ATP-based luminescent cell viability assay 
(CellTiter-Glo) to determine median lethal concentrations (LC50s) 
at 48 hours (Figure 1B) after treatment initiation, and observed a 
Figure 2. Mechanism of 6-ETI–induced cell death. (A) BC3 cells treated with the indicated doses of 6-ETI at the shown time points were analyzed by 
Western blotting on whole cell extracts for PARP cleavage as an indicator of apoptotic induction and for LC3B cleavage as an indicator of autophagosome 
formation. Actin was used as a loading control, and results shown are representative of at least 3 independent experiments. (B) BC3 cells were pretreated 
or not with 80 μM zVAD-FMK, a pan-caspase inhibitor, to inhibit apoptosis. After 3 hours, cells were treated at the indicated doses of 6-ETI. Cells lysed at 
48 hours were examined by CellTiter-Glo to measure viability, with results normalized to untreated cells at each condition. The mean ± SEM of 3 indepen-
dent experiments is shown. (C) BC3 cells treated with DMSO or 1 μM 6-ETI for 24 hours were stained with propidium iodide, followed by flow-based cell 
cycle analysis. The obtained histograms were modeled by FlowJo. Results shown are representative of at least 3 independent experiments. (D) BC3 cells 
were treated with DMSO or 1 μM or 10 μM 6-ETI for 24 hours, then labeled with 10 μM EdU for 2 hours. EdU incorporation into the newly synthesized DNA 
was visualized by staining of cells using Click-iT EdU Alexa Fluor 488 cocktail, and the nucleus was counterstained using Hoechst. Immunofluorescence 
images are representative of 2 independent experiments. (E) Immunoblotting for γH2AX is shown after treatment with 6-ETI at the indicated time points 
and doses. Result shown is representative of 3 independent experiments. (F) Representative immunofluorescence images of 2 independent experiments 
showing nuclear localization of γH2AX after treatment with 6-ETI for 48 hours. As a positive control, BC3 cells were treated with UV radiation to induce 
DNA damage. See related Supplemental Figure 2 for BC1 data. Original magnification, ×100.
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there is no toxicity or any other appreciable effects in resistant cell 
lines. PARP cleavage was used as a marker of apoptosis in PEL 
cells treated with 6-ETI. As seen in Figure 2A and Supplemental 
Figure 2, 6-ETI induced small but observable increases in apop-
tosis in BC1 and BC3 cells at the 1 μM dose as early as 24 hours. 
Because KSHV vFLIP has also been implicated in autophagic cell 
death, we performed Western blotting to determine the extent 
of activation of this pathway after 6-ETI treatment in PEL cells. 
There was some induction of autophagy, as assessed by appear-
PEL cells undergo apoptosis and necrosis upon 6-ETI treatment. 
In order to determine the mechanism of 6-ETI–induced cell death, 
we examined treated cells for activation of classical cell death path-
ways, including apoptosis, autophagy, and necrosis. We tested the 
effect of treatment of 2 PEL cell lines with 1 μM 6-ETI, as this con-
centration is close to the LC95, which allowed us to capture the full 
effect of the drug while not having any effect in resistant cell lines. 
We also tested 10 μM, which exceeds the effective concentration 
but provides information on earlier effects and is a dose at which 
Figure 3. 6-ETI is effective in vivo in a PEL xenograft mouse model. (A) Scheme of BC3-luc tumor cell engraftment in NOD/SCID mice and treatment with 
6-ETI. (B) NOD/SCID mice randomized into vehicle (n = 10), low-dose (150 mg/kg/d) (n = 10), and high-dose (300 mg/kg/d) (n = 10) treatment groups after 
BC3NFRen-luc#3 tumor engraftment were followed by weighing and luciferase imaging in vivo to follow tumor progression. Mice in both treatment groups 
were treated for 2 separate 9-day intervals as indicated. Representative results from the first trial of 2 are shown. (C) Quantitation of tumor burden by 
bioluminescence imaging from 2 independent trials. Data are shown through day 41. Statistical analysis was performed using 1-way ANOVA (P = 0.0032 at 
day 11 after treatment). Statistical analysis comparing vehicle- and low and high dose–treated mice separately at specific time points was also performed 
using unpaired t test (*P ≤ 0.05). (D and E) Kaplan-Meier analysis of progression-free survival (n = 22) (D) and overall survival (n = 30) (E) was performed on 
all mice from both trials, and the results are color-coded by treatment group. In the progression-free survival curve (D), the low-dose (n = 8) and high-dose 
(n = 4) treatment arms showed complete overlap, as by day 100 all live mice were tumor free, and none had died of tumor. The difference in survival curves 
was analyzed by log-rank (Mantel-Cox) test (P < 0.0001).
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as determined by caspase-independent cell death. In order to do 
this, we pretreated PEL cells with the pan-caspase inhibitor zVAD-
FMK, followed by 6-ETI treatment at selected doses (Figure 2B). 
PEL cells pretreated with zVAD-FMK still underwent cell death 
upon 6-ETI treatment compared with untreated cells. This con-
firmed that 6-ETI–induced cell death is largely caspase-indepen-
ance of the LC3B cleavage product, apparent at the 1 μM dose at 
the 24 hour time point (Figure 2A and Supplemental Figure 2).
Cells with low ATP levels have been observed to preferentially 
undergo necrosis over apoptosis (12). Since 6-ETI–treated cells 
have low ATP content upon treatment as determined by CellTiter-
Glo assay, we examined PEL cells for the appearance of necrosis, 
Figure 4. ADK is required for 6-ETI activation. (A) Figure indicates locations of independent recurrent mutations G239E and E243K on ADK, discovered 
by SNP calling on RNA-Seq data from 6-ETI–resistant clones. Schrödinger’s Maestro was used to model ADK binding to adenosine (ADO) (top panel), and 
postulated binding to 6-ETI (bottom panel). (B) BC3 cells treated at a range of concentrations of A-134974 or ABT-702 were analyzed by CellTiter-Glo assay 
for viability at 48 hours. Results are shown as the mean ± SEM of at least 3 independent experiments where LC50s were determined using online EC50 soft-
ware. (C) 6-ETI viability dose curves were set up on BC3 cells pretreated with 1 μM ADK inhibitors A-134974 and ABT-702 or DMSO, followed by treatment 
with 6-ETI. The fold increases in 6-ETI LC50s are shown via bar graph, representing the mean ± SEM of at least 3 independent experiments. (D) ADK kinase 
assay to test 6-ETI phosphorylation was carried out by mixing of kinase assay components with 6-ETI, followed by acetonitrile quenching at various time 
points. Reaction mixture at each time point was injected into HPLC to detect the appearance of the phosphorylated peak. Chromatogram for the 6-ETI 
standard under the HPLC conditions indicates the appearance of a peak at retention time 1.76 minutes, indicated by a star. Chromatograms at t = 0 and  
t = 60 minutes both contain this peak, while t = 60 reveals the appearance of a secondary peak at 1.57 minutes (indicated by double star). (E) Mass spec-
trometry analysis was performed on the fraction of the t = 60 reaction mixture retrieved at 1.57 minutes of HPLC. The MS revealed a prominent peak at 
391.3 (indicated by asterisk), corresponding exactly to the expected molecular weight of phospho–6-ETI.
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dent, and that necrosis is a major pathway of cell death induced by 
this compound, although apoptosis and autophagy also occur, at 
least in a subset of cells and under some experimental conditions.
6-ETI induces S phase arrest. We examined effects on the cell 
cycle upon 6-ETI treatment by propidium iodide flow cytometry. 
We observed an increase in the fraction of cells in the sub-G0 
phase upon 6-ETI treatment, likely reflective of some apoptosis, 
but we also detected a reproducible increase in the percentage of 
cells in S phase 24 hours after treatment in BC3 cells. This repre-
sents an induction of S phase arrest by the compound, as modeled 
by FlowJo (Figure 2C). This accumulation of cells in the S phase 
is consistent with incorporation of 6-ETI into DNA during DNA 
synthesis, thereby blocking extension and causing stalling of rep-
lication forks. We investigated the effect of 6-ETI on DNA syn-
thesis by using a Click-iT 5-ethynyl-2′-deoxyuridine (EdU) assay, 
which showed a complete inhibition of DNA synthesis upon 1 μM 
treatment of 6-ETI for 24 hours (Figure 2D). Similarly, we also 
observed reduction in BrdU incorporation upon exposure to 6-ETI 
treatment (data not shown). This process leads to the formation 
of double-stranded breaks in DNA, thus triggering a DNA damage 
response, a phenomenon that has been observed with other nucle-
oside analogs (13). To determine whether 6-ETI similarly triggers 
a DNA damage response, we assessed 6-ETI–treated PEL cells for 
the presence of γH2AX, a well-known marker of double-stranded 
breaks. Immunoblot analysis showed the 
appearance of γH2AX at 24 hours after 
treatment with 1 μM and 10 μM doses of 
6-ETI (Figure 2E and Supplemental Fig-
ure 2). Nuclear accumulation of γH2AX 
was also seen by immunofluorescence 
(Figure 2F), confirming that 6-ETI induc-
es DNA damage.
6-ETI does not inhibit viral latent pro-
tein levels. Since several viral latent pro-
teins have been shown to directly modify 
important cellular signaling pathways, 
such as vFLIP’s critical role in sustained 
NF-κB induction in PELs (7), and since 
6-ETI was isolated using a PEL-specific 
NF-κB reporter assay, we postulated 
that this compound may exert its effects 
on PEL cell viability and NF-κB signal-
ing through inhibition of vFLIP or other 
oncogenic viral gene products. Accord-
ingly, we examined the levels of the 
major KSHV latent proteins upon 6-ETI 
treatment by immunoblotting. Howev-
er, no reduction was seen in latent viral 
protein expression (Supplemental Fig-
ure 3A). This unexpected effect was also 
observed when we examined treated cells 
for levels of these transcripts by quantita-
tive reverse transcription PCR at 24 hours 
(Supplemental Figure 3B).
Since lytic reactivation triggered by 
the compound could be a mechanism of 
cell death, we examined 6-ETI’s effects on 
viral lytic gene expression. Analysis of immediate-early (ORF50) 
and late lytic transcripts (K8.1) by quantitative reverse transcription 
PCR demonstrated a minor induction of immediate-early and mild 
suppression of late transcripts at the highest dose (Supplemental 
Figure 3B). The immediate-early gene viral IL-6 (vIL-6), which has 
also been found to be expressed at low levels during latency (14), 
was increased in expression at higher doses, paralleling the other 
latent genes. To further investigate the compound effects on the 
lytic viral cycle, we used the JSC1 PEL cell line infected with recom-
binant KSHV (rKSHV.219), which expresses GFP under the control 
of the EF1-α promoter in all cells and red fluorescent protein (RFP) 
under the control of the early lytic PAN promoter of KSHV (15). 
This cell line thus expresses GFP constitutively, and RFP only when 
the lytic cycle is activated. As Supplemental Figure 3C shows, there 
was an induction of lytic reactivation by 6-ETI compared with the 
lytic phase inducer 12-O-tetradecanoylphorbol-13-acetate (TPA) 
in a small proportion of cells, which increased at higher doses and 
longer time points. This induction of lytic reactivation does not 
explain the cell death that occurs in a larger proportion of PEL cells 
with toxic doses of 6-ETI.
6-ETI is highly effective in vivo. We tested 6-ETI using a trace-
able reporter xenograft model of PEL (6). We treated cohorts of 10 
mice with vehicle alone or 150 or 300 mg/kg/d 6-ETI for 9 days 
(Figure 3A). These doses were selected based on NIH in vivo anti-
Figure 5. ADK levels determine sensitivity to 6-ETI. (A) A panel of KSHV+ and KSHV– lymphoma cell 
lines were plated at viability assay conditions (i.e., 1 × 105 cells/ml in RPMI with 20% FBS), and whole 
cell extracts obtained at 24 hours were examined for ADK levels by Western blotting. GAPDH was used 
as a loading control. Results shown are representative of more than 3 independent experiments. (B) 
Successful lentiviral shRNA-mediated knockdown of ADK in the pancreatic adenocarcinoma cell line PA-
Tu-8988T was examined by Western blot using an ADK antibody. A representative blot of 3 independent 
experiments is shown. 6-ETI viability assays at 24 hours were performed on the knockdown cell line com-
pared with control. LC50 graphed is the average of 5 independent experiments (mean ± SEM). Statistical 
analysis was performed using Mann-Whitney unpaired test (P = 0.0079, **P ≤ 0.05). (C) ADK normally 
phosphorylates adenosine to convert it into adenosine monophosphate (AMP) and similarly adds a 
phosphate from ATP into 6-ETI to convert it into p6-ETI. (D) PEL cell lines BC3 and BC2 and DLBCL cell 
line IBL1 were treated with increasing concentrations of 6-ETI and phospho–6-ETI for 48 hours. Results 
plotted are the average of 4 independent experiments (mean ± SEM). Statistical analysis was performed 
using Mann-Whitney unpaired test (P = 0.0317, *P ≤ 0.05).
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cancer drug screens with this drug, which used 200 mg/kg for 9 
days with no reported toxicities. Luciferase imaging in vivo clear-
ly showed a striking and immediate regression of the implanted 
xenograft within 3 days of treatment, which began at day 5 after 
engraftment (Figure 3B). Quantification of the luminescent sig-
nal as a measure of tumor burden is shown in Figure 3C. In 2 mice 
treated at the lower dose level (150 mg/kg/d), tumor recurred 2 
months after cessation of treatment, but responded again upon 
retreatment, documenting an impressive response in cases of both 
incipient and well-established tumors. Kaplan-Meier analysis of 
Figure 6. Expression of ADK and sensitivity to 6-ETI in plasma cell tumors. (A) BC3 cells’ ADK expression was evaluated by immunohistochemistry in the 
BC3 cell line, hyperplastic tonsils, and PEL, MM, and plasmablastic lymphoma primary tumors (original magnification, ×60). Inset: In the image of a tonsil 
section, a positive cell with morphological features of a plasma cell is enlarged. Two-color immunohistochemistry showing a high-power image of plasma 
cells expressing both ADK and CD138. (B) LC50s for MM cell lines treated with 6-ETI for 48 hours were determined by CellTiter-Glo assay. BC3 was used as 
a positive control and IBL1 as a negative control for drug sensitivity. Shown is the mean ± SEM of 2 independent experiments, where each condition was 
performed in duplicate in each experiment. (C) U266 cells were treated with DMSO or 5 μM 6-ETI for 24 hours, then labeled with 10 μM EdU for 2 hours. EdU 
incorporation into the newly synthesized DNA was visualized using Click-iT EdU assay. The immunofluorescence images are representative of 2 indepen-
dent experiments. Original magnification, ×100. (D) MM patient specimens (n = 9) were treated with increasing concentrations of 6-ETI ex vivo, followed by 
analysis for ATP content by CellTiter-Glo assay at 24 hours. LC50s were determined using GraphPad Prism. (E) Flow cytometry analysis showing the number 
of normal plasma cells isolated from human tonsils (CD19–, CD138+) before and after 6-ETI treatment. Data are representative of 2 independent experiments.
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mation regarding either the target of the compound or other path-
ways important for its mechanism of action. Both human and KSHV 
genomes were used as reference sequences for comparison, in 
order to enable comprehensive target identification. The only recur-
rently altered gene identified by single-nucleotide variant analysis 
of the RNA sequencing data was adenosine kinase (ADK). We found 
2 independent mutations (G239E and E243K) in this gene in 2 unre-
lated resistant clones (Figure 4A and Supplemental Table 3).
6-ETI requires endogenous ADK for activity. ADK is the enzyme 
that catalyzes the transfer of γ-phosphate from ATP to adenosine 
or inosine, forming AMP and ADP in the process. This reaction 
thus constitutes the first step of de novo purine biosynthesis, and 
makes ADK an essential enzyme whose knockout is lethal in mice 
(16). ADK is required to control levels of cellular adenosine, which 
can be toxic if left unregulated (17), while ADK inhibition serves a 
host of other protective signaling functions (18, 19).
The ADK mutations were modeled based on the x-ray crys-
tallographic structure of human adenosine kinase (1BX4) using 
Maestro (Schrödinger) (Figure 4A). We found that the mutated 
residues do not directly interact with the substrate or residues in 
the substrate-binding site, but are close to it and therefore may 
conceivably contribute to the observed phenotype by affecting the 
conformational dynamics of the kinase. We examined this gene 
in depth across all 7 resistant clones, and found recurrent chang-
es in the form of exon loss sparing the active site in 3 additional 
cases (Supplemental Table 3 and Supplemental Worksheet 2). In 
the 2 cases where there were no mutations or active site deletions, 
there was a significant (10-fold) downregulation of gene expres-
sion compared with that in the control cell lines. These results 
indicated that ADK inactivation confers PEL cell resistance to 
6-ETI. Conversely, there were no recurrent missense or nonsense 
mutations in KSHV genes occurring within the resistant cell lines, 
or significant changes in viral gene expression. There was no over-
the trials indicated a startling protective effect of 6-ETI treatment 
on the length of progression-free survival in mice (Figure 3D; P < 
0.0001), with the study being terminated at the 100-day mark. 
There were no obvious toxicities from the treatment, although a 
few long-surviving mice in the treatment groups succumbed to 
unrelated infections at the site of repeated luciferase injection. 
Nevertheless, both low-dose- and high-dose-treated mice had a 
significant prolonged overall survival compared with untreated 
mice, as shown in Figure 3E.
Mechanism of selectivity revealed by unbiased genomic analysis. In 
order to determine the primary target of 6-ETI at effective doses, 
we performed unbiased genomic sequencing of resistant clones 
obtained from the parental PEL cell line BC3 through selection. We 
used transcriptome sequencing for this analysis, in order to simul-
taneously obtain gene sequences and expression levels. To produce 
resistant clones, BC3 cells were grown in 96-well plates at escalating 
doses of compound up to 10 μM over the course of several months, 
and the resultant clones were tested by viability assay for sensi-
tivity to the compound. We successfully obtained 6 independent 
clones arising from different wells of 2 plates, NSCE-1, NSCE-2, 
NSCE-3, NSCE-6, NSCE-7, and NSCE-8, that were fully resistant to 
6-ETI (Supplemental Figure 4). Additionally, we were able to cul-
ture ex vivo tumor cells from 2 mice in the low-dose cohort of the 
xenograft trial that developed late recurrent tumors after 2 rounds 
of treatment, and place these under selection with 6-ETI to yield 
completely resistant xenograft outgrowth clones. These cell lines 
were designated 2-3low and 3-5low (Supplemental Figure 4).
We extracted RNA from resistant clones and duplicate samples 
of the parental cell line, and performed transcriptome sequencing 
followed by bioinformatic analysis (51 bp single-end reads, mean 
library size 58.5 million reads per clone) to identify mutations 
linked to resistance. We reasoned that recurrently observed muta-
tions across multiple independent clones might provide key infor-
Figure 7. 6-ETI inhibits tumor growth in a disseminated MM 
mouse model. (A) A schematic of engraftment of CAG-luc 
MM cell line into NOD/SCID mice and treatment with 6-ETI. 
(B) When tumors engrafted (at day 8), mice were injected 
i.p. with vehicle (7 mice on the left) or 6-ETI (8 mice on the 
right) for 9 days at 200 mg/kg/d, and tumor progression was 
monitored using in vivo luciferase imaging. (C) Biolumines-
cence representing tumor burden after 20 days of follow-up 
in the vehicle-treated (blue line) versus 6-ETI–treated group 
(red line) is indicated. Statistical analysis was performed 
using unpaired t test (**P = 0.0076 at day 20 after treat-
ment and P < 0.05 at other time points indicated by *). (D) 
Kaplan-Meier survival analysis was performed on all mice, 
and the results are color-coded by treatment group. The dif-
ference in survival curves was analyzed by log-rank (Mantel-
Cox) test (P = 0.0010).
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analysis to enable identification of the putative phospho–6-ETI 
product. HPLC revealed the appearance of a second peak with a 
lower retention time (1.57 minutes) compared with the 6-ETI stan-
dard (1.76 minutes) as early as 5 minutes after the start of the reac-
tion, and more apparent at 60 minutes (Figure 4D). MS analysis of 
the 1.57-minute eluent from the 60-minute sample indicated that 
this new peak contained a primary species of 391.3 Da (Figure 4E). 
According to the [M – H] rule for negative electrospray mode of MS, 
this corresponds exactly to the expected molecular weight of acti-
vated phospho–6-ETI, thus conclusively proving that ADK phos-
phorylates 6-ETI directly.
Endogenous ADK levels determine sensitivity to 6-ETI. We 
assessed whether expression of higher levels of ADK enabled 
enhanced processing of 6-ETI into its active phosphorylated form, 
which could explain the selectivity of 6-ETI to PEL cells. A panel of 
representative PELs and non-PELs were examined for ADK expres-
sion by immunoblot 24 hours after plating at cell densities used for 
the viability assays (Figure 5A). Results clearly indicated that PEL 
cell lines express higher ADK levels than non-PEL, consistent with 
their heightened sensitivity to 6-ETI. To confirm that this endoge-
nous ADK is necessary to confer sensitivity to 6-ETI, we attempted 
to knock down ADK in PEL cell lines using lentiviral transduction, 
but complete suppression was not achieved. Therefore, we used 
a carcinoma cell line (PA-Tu-8988T), also with high ADK expres-
sion, which is more amenable to lentiviral transduction, to test 
whether genetic suppression of ADK affects sensitivity to 6-ETI. 
In this experiment, ADK knockdown resulted in a log increase in 
LC50 (Figure 5B). Thus, ADK activity appears to be a prerequisite for 
susceptibility to 6-ETI. To further test the model that ADK converts 
6-ETI into its monophosphorylated active form (Figure 5C), we syn-
thesized phospho–6-ETI and tested it in PEL and the resistant IBL1 
cell line. Figure 5D shows that this modification partially overcomes 
resistance in IBL1 cells that express low levels of ADK.
We also examined ADK levels for 3 different resistant cell lines 
at higher plating densities, and found that there was a clear upregu-
lation of ADK with crowding, although this was most robust for the 
IBL1 cell line, which is an EBV-infected immunoblastic lymphoma 
(Supplemental Figure 5A). If ADK expression levels were a major 
determinant of susceptibility to 6-ETI treatment, then sensitivity 
in non-PEL cell lines may be induced at plating conditions that 
increase their endogenous ADK levels. To test this hypothesis, we 
plated resistant IBL1, LY7, and BCKN1 cells at higher cell density 
(5 × 105 cells/ml), and performed viability assays using 6-ETI dose-
response curves. The LC50s under these alternate plating condi-
tions decreased strikingly from those determined at the original 
assay conditions, showing that sensitivity in resistant lymphoma 
cell lines could be induced by altered cell densities (Supplemental 
Figure 5B). Taken together, these data show that there is a strong 
correlation between ADK levels and sensitivity to 6-ETI, explain-
ing the selectivity of PEL cells for 6-ETI–induced toxicity.
We further tested the idea that different experimental condi-
tions, and specifically in vivo growth of some tumor cells as would 
occur in naturally occurring malignancies, are associated with high 
ADK expression, which could predict response to 6-ETI treatment. 
As proof of principle, we examined whether the immunoblastic 
lymphoma cell line IBL1 expresses ADK in vivo using a mouse 
xenograft model and assessed tumor responses following treat-
expression of multidrug efflux pumps either, although there were 
transcriptional changes in a number of genes (complete list pro-
vided in Supplemental Worksheet 1).
The inactivation of ADK in every single resistant clone sug-
gests 2 alternative scenarios: (a) that ADK is a direct target of 6-ETI 
and that ADK is necessary for the survival of PEL cells; or (b) that 
6-ETI is a prodrug that is activated by ADK. The latter possibil-
ity is supported by previous data indicating that ADK can activate 
other nucleoside analogs, including several important antiviral 
compounds such as ribavirin (20–22), triciribine (23), mizoribine 
(24), and tiazofurin (25), although these compounds can also be 
activated by a variety of other kinases (26). Such a model was also 
supported by the locations of the observed mutations, one at and 
one near the active site of the enzyme, suggesting the involvement 
of such interactions in drug activity.
In order to differentiate between these 2 scenarios, we first 
treated BC3 cells with 2 different ADK inhibitors, A-134974 (27) 
and ABT-702 (28), and showed that neither of these inhibitors 
showed toxicity, with LC50s in BC3 cells of greater than 10 μM 
(Figure 4B), in contrast to their known IC50 of ADK inhibition in 
intact cells of 50 nM and 51 nM, respectively. To test the alterna-
tive model that ADK activates 6-ETI, we performed 6-ETI viability 
assays in PEL cells that were pretreated with these highly selective 
ADK inhibitors. We demonstrated through competitive viability 
curves on BC3 cells that pretreatment with these inhibitors effec-
tively rescued PEL cells from cell death induced by 6-ETI treat-
ment (Figure 4C).
The mechanism of activation of some nucleoside analogs by 
ADK involves phosphorylation at the 5′ end of the “prodrug,” con-
verting the molecule into the active “drug” form (29). We exam-
ined whether 6-ETI is similarly phosphorylated by ADK using an in 
vitro kinase assay in which ADK and ATP were mixed with 6-ETI 
and quenched by acetonitrile at different time points. Samples 
were injected into an HPLC, followed by mass spectrometry (MS) 
Figure 8. Model for 6-ETI’s mechanism of action. 6-ETI competes with 
adenosine (ADO) and other nucleosides for binding to and phosphoryla-
tion by ADK, which inhibits ATP-dependent metabolic processes. This also 
allows 6-ETI to be phosphorylated and activated by ADK, with subsequent 
phosphorylation steps that allow the compound to be incorporated into 
DNA and possibly RNA, leading to DNA synthesis inhibition, DNA damage 
response, and cell death.
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whether 6-ETI may be toxic to normal plasma cells, we treated 
total tonsil B lymphocytes with 1 μM and 10 μM 6-ETI for 24 hours 
and subsequently gated for plasma cells (CD19–, CD138+). We did 
not find a decrease in the total number or proportion of plasma 
cells (Figure 6E) upon treatment, so we conclude that while these 
express high levels of ADK, they are not sensitive, likely because 
they are not proliferative.
Effectiveness of 6-ETI in a disseminated mouse model of MM. 
Given the in vitro sensitivity data, we also assessed the antitumor 
activity of 6-ETI in a disseminated MM xenograft model by inject-
ing NOD/SCID mice i.v. with Luc+GFP+ CAG cells stably express-
ing the HSV-TK-eGFP-luciferase fusion protein. Before injection, 
we confirmed that CAG-luc cells expressed monotypic cytoplas-
mic light chains and ADK (Supplemental Figure 7C). Anatomical 
distribution and pathophysiological manifestation of this model 
were compatible with the clinical course of MM in humans, i.e., 
hallmarked by malignant plasma cells present mainly within the 
bones (sternum, femur, tibia, vertebrae, skull, mandible) and asso-
ciated with multifocal lytic bone lesions (Supplemental Figure 7C). 
We monitored tumor burden by bioluminescence imaging. Seven 
mice were treated with vehicle, and 8 with 200 mg/kg/d of 6-ETI 
(Figure 7A). We found that mice treated with 6-ETI had significant 
reduction in tumor burden as assessed by the bioluminescent sig-
nal (Figure 7, B and C) without any weight loss. Moreover, over-
all survival was also significantly prolonged in the 6-ETI–treated 
group compared with the control mice (Figure 7D; P < 0.005).
Comparison with other nucleoside analogs. We tested whether 
the selectivity profile of 6-ETI to PEL and MM is unique or is a 
general feature of related nucleoside analogs. We first tested 
6-mercaptopurine (6-MP) (Table 1). 6-ETI is structurally similar 
to 6-MP, but the latter lacks the ribose ring where phosphorylation 
occurs. Interestingly, 6-MP, while not particularly effective against 
PEL cells, demonstrated selectivity to them, much like 6-ETI, sug-
gesting that it may be metabolized to an intermediate that may be 
phosphorylated by ADK, albeit with low efficiency (Table 1). We 
also tested 4 different purine analogs that are FDA approved: vida-
rabine, didanosine, cladribine, and fludarabine phosphate. None 
of these showed the same spectrum of selectivity or effectiveness 
toward PEL and MM as 6-ETI. To test whether a pyrimidine ana-
log would have an effect toward PEL and MM, we tested ribavirin. 
This drug has received recent attention for its effect on leukemias 
acting as a protein synthesis inhibitor, in addition to its antiviral 
effects (33). However, this drug had an effect on the viability of 
the 2 lymphoma lines tested only at very high concentrations (LC50 
>44 μM), and even higher for MM (LC50 >>100 μM).
Discussion
This study reports the successful identification of what we believe 
is the first novel and selective inhibitor of KSHV-associated PEL 
that clearly exhibits preclinical potential, as evidenced by thera-
peutically relevant LC50s and striking effectiveness in vivo in mouse 
models. In addition, we demonstrated the feasibility of identifying 
the mechanism of selectivity, in this case activation of the prodrug 
by endogenous ADK, by using RNA-Seq–based resistome analysis 
as a methodology that has not, to our knowledge, been previously 
described for this purpose. We further report expression of ADK in 
human plasma cells and other lymphoid malignancies of plasma 
ment with 6-ETI. We found that this compound reduced the rate 
of tumor growth in mice, although responses were not as dramatic 
as those seen in PEL (Supplemental Figure 5C). Ex vivo tumors 
from these mice demonstrated expression of ADK in a proportion 
of tumor cells, as evaluated by immunohistochemistry, as well as 
some apoptosis induced by treatment in vivo, as determined by 
increased cleaved caspase-3 positivity (Supplemental Figure 5D). 
Thus, expression of ADK in vivo is associated with partial tumor 
responses to 6-ETI in an EBV+ immunoblastic lymphoma cell line.
ADK expression may be used as a biomarker for sensitivity to 
6-ETI. The clear correlation between 6-ETI sensitivity and ADK 
expression strongly suggested that other malignancies that express 
ADK may be sensitive to this drug. However, there is little infor-
mation regarding ADK expression in lymphoid tissues and lym-
phoid malignancies, and cancer in general, in vivo. We therefore 
performed immunohistochemistry for ADK in human tonsils, and 
found that normal plasma cells are positive, based on morphol-
ogy and costaining with CD138 (Figure 6A). We also confirmed 
expression of ADK in primary biopsy samples of PEL and extra-
cavitary PEL. Given that PEL most closely resembles plasma cells 
immunophenotypically (CD138+) and by gene expression profiling 
(30–32), we hypothesized that ADK is highly expressed in other 
malignancies of plasma cell origin, namely multiple myeloma 
(MM) and plasmablastic lymphoma. All 4 cases of MM and both 
cases of plasmablastic lymphoma evaluated showed clear expres-
sion of ADK (Figure 6A and Supplemental Figure 6). We therefore 
evaluated 4 MM cell lines, JJN3, MM1S, U266, and CAG, for their 
sensitivity to 6-ETI treatment. As was the case for PEL, MM cell 
lines were sensitive to inhibition by 6-ETI and phospho–6-ETI, 
with LC50s in the high nanomolar range (Figure 6B and Supple-
mental Figure 7A). Primary MM samples cultured ex vivo also 
showed sensitivity to 6-ETI, indicating that this sensitivity is not 
exclusive to cell lines (Figure 6D). Coculture with bone marrow 
stromal cells during treatment was assessed for 2 different patient 
samples, in parallel with separated myeloma cells alone, and there 
was no significant difference in sensitivity. 6-ETI also suppressed 
DNA synthesis in MM cells (Figure 6C), and cytotoxicity was 
associated with induction of apoptosis, autophagy, and activation 
of a DNA damage response (Supplemental Figure 7B). To assess 
Table 1. Comparison of 6-ETI with other nucleoside analogs that 
are FDA approved, using a PEL cell line (BC3), an MM cell line 
(U266), and an EBV+ DLBCL cell line (IBL1)
Nucleoside analog  
tested
LC50 BC3 (PEL) 
(nM)
LC50 U266 (MM) 
(nM)
LC50 IBL1 (DLBCL) 
(nM)
6-ETI 49.79 437.35 >>100,000
Ribavirin 44,739 >>>100,000 46,487
Vidarabine >>100,000 >>100,000 >>100,000
Didanosine >>100,000 >>100,000 >>100,000
6-Mercaptopurine 5,143 10,325 >100,000
Cladribine 5,237 29,192 290.2
Fludarabine >>>100,000 90,690 28,853
Sensitivity after 48 hours of treatment is shown. Results shown are 
LC50s from viability assays (CellTiter-Glo) where the mean ± SEM of 2 
independent experiments performed in duplicates is provided. 
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targets within the cell. To our knowledge, our study is the first to 
date to effectively demonstrate the use of transcriptome sequenc-
ing of drug-resistant clones to determine a definitive mechanism 
of specificity for a novel lymphoma inhibitor discovered through 
targeted screening. This is of particular importance in cases of 
functional screens that identify effective inhibitors with unknown 
primary targets, such as in this case, wherein the primary high-
throughput screen for NF-κB inhibitors yielded a hit compound 
that inhibits this pathway as a secondary mechanism. Additionally, 
the gold standard for target identification, stable isotope labeling 
of amino acids in cell culture (SILAC), is restricted to molecules 
that retain activity when structurally modified with a tag, and have 
a direct molecular target rather than metabolic effects on the cell. 
Both requirements preclude its utility in the case of 6-ETI. Thus, 
we demonstrated effective use of a novel methodology to over-
come the constraints of existing methods for target identification.
The finding that ADK directly activates 6-ETI by phosphoryla-
tion provides an important benchmark in further development of 
this compound as an anticancer agent, as well as suggesting a prob-
able mechanism of specificity. Specifically, since the normal func-
tion of ADK is to phosphorylate adenosine to its monophosphory-
lated form AMP, thus catalyzing an early step in purine nucleoside 
biosynthesis, we can postulate a model whereby enhanced ADK 
expression levels in sensitive cells effectively carry out rapid drug 
activation, enabling it to reach its “true” target(s) within the cell. 
In fact, the close structural similarity of 6-ETI to inosine, along 
with the prevalence of replication/transcription/translation and 
nucleotide metabolism pathways in the expression analysis, sug-
gests that the drug may act as a subversive substrate for ADK, 
and thus induce aberrant replication by its inclusion into DNA. 
We have shown that 6-ETI can significantly affect DNA synthesis 
using Click-iT EdU assay (Figure 2D and Figure 6C); whether it 
can directly incorporate into DNA is still to be determined. This 
possibility of DNA incorporation is supported by the precedent of 
the nucleoside analog antiviral agents such as acyclovir and gan-
ciclovir, both of which incorporate into viral and cellular DNA to 
prevent viral replication and cell division (42). The ADK-activated 
nucleoside analog ribavirin is also known to incorporate into viral 
nucleic acids (43), and functions primarily through its competition 
with adenosine and guanosine for dependent processes, such as 
transcription (44). The only previously published studies on 6-ETI 
also indicate that the compound effectively inhibits DNA synthe-
sis (45) and replication of RNA viruses (38). Significantly, much 
like topoisomerase inhibitors, 6-ETI induces S phase arrest in PEL 
cells, consistent with a direct effect on DNA replication.
The discovery that ADK overexpression enhances sensitivity to 
6-ETI immediately expanded the scope of utility for an inhibitor 
that was initially found to be highly PEL cell–specific. This expec-
tation was reflected in the high expression of ADK in MM tissues 
and concordant sensitivity of cell lines to this compound (Figure 7). 
This is consistent with public data in Oncomine (www.oncomine.
org), which also shows overexpression of ADK RNA in MM (as 
the sole hematological malignancy expressing this gene). Encour-
agingly, recent entrants to the antitumor PNA arsenal such as 
8-chloro-adenosine and 8-amino-adenosine have been found to be 
effective in MM (46–48), directly mediating their effects through a 
decrease in ATP and DNA and/or RNA synthesis, but these are not 
cell origin, including MM. We confirmed the relevance of ADK 
expression and its potential to be used as a biomarker to identify 
sensitive cancers by documenting in vitro and in vivo responses of 
MM and PEL to 6-ETI.
The idea that purine analogs function as drugs through their 
effects on metabolism was proposed in seminal work by Elion and 
Hitchings in 1965 (34). This class of compounds has been studied 
over the last 50 years in an effort to develop and improve them as 
effective anticancer and antiviral agents. In recent years, purine 
nucleoside analogs (PNAs) have found favor in cancer and antivi-
ral clinical trials. Studies of their mechanisms of action have iden-
tified several universal themes. PNAs appear to require phosphor-
ylation for conversion to their active forms within the cell, which 
can include mono-, di-, or tri-phosphorylation steps. The active 
compounds have multiple “targets” within the cell. Chiefly, they 
inhibit metabolism by outcompeting ATP, and inhibiting cellular 
kinases. Additionally, by dint of their structural similarity, they 
are usually able to incorporate into DNA and/or RNA, thus lead-
ing to chain termination and abrogating synthesis (35, 36). A resul-
tant accumulation of double-strand breaks in the cell triggers the 
apoptotic cascade. By reasons of precedent and as a novel PNA, we 
propose that 6-ETI is activated by ADK and has deleterious effects 
on sensitive cells through similar mechanisms, which is supported 
by our experimental data (Figure 8).
Several pieces of evidence suggested that 6-ETI functions as 
an antimetabolite in PEL cells. Adenine derivatives with a 6-S sub-
stitution have been extensively studied as anticancer and antiviral 
agents (37–39). The prototypical compound of this class of mole-
cules is 6-mercaptopurine (6-MP) (Table 1), which shares structur-
al similarity with 6-ETI. Since 6-MP is an established antiviral that 
functions through effects on ribonucleotide pool size (38), it is pos-
sible that 6-ETI may also exert effects on nucleotide or nucleoside 
metabolism. RNA-Seq on 6-ETI–resistant clones was useful to 
detect changes in gene expression patterns (Supplemental Work-
sheet 1) that can be used to uncover pathways and signatures. This 
analysis yielded several folate, purine, and pyrimidine biosynthet-
ic pathways prominently among the top hits by Ingenuity Pathway 
Analysis (QIAGEN) (Supplemental Table 4 and Supplemental 
Worksheet 3). However, owing to poor enrichment of nucleotides 
extracted by conventional methods in PEL cells, possibly attribut-
able to high levels of endogenous nucleotidases, examination of 
such an effect directly in these cells has been challenging. Addi-
tionally, sensitive cell lines showed a dramatic reduction in ATP 
levels upon 6-ETI treatment, when measured by CellTiter-Glo, 
consistent with effects observed in other PNAs (Figure 1B). Nota-
bly, as part of preliminary experiments to determine the drug tar-
get, we cultured resistant cell lines in modified media with stable 
isotope-labeled arginine and lysine, which caused the LC50s for 
6-ETI in these cell lines to plummet to levels observed in sensi-
tive cell lines. In this regard, assessment of RNA expression data 
showed an enrichment of amino acid metabolic pathways in resis-
tant clones (Supplemental Table 4).
RNA-Seq–based target identification for drugs with unknown 
mechanisms of action is a novel methodology proposed by Elemen-
to and colleagues (40). This approach was recently used to iden-
tify mechanisms of drug resistance for the established anticancer 
agents ispinesib and YM155 (41), both of which have well-known 
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well known to have challenging druggability. The use of unbiased 
genomics to analyze the resistome of drug-resistant cell lines pro-
vides important proof of principle in target identification, espe-
cially for compounds failing the narrow structural and functional 
criteria required by conventional methods such as SILAC. ADK is a 
relatively unknown player in the field of oncological therapeutics, 
and its critical role in activation of this new anticancer drug justi-
fies further testing in this context.
We propose that once preclinical testing is completed, 6-ETI 
is a viable candidate for clinical trials in patients with lymphoid 
malignancies, using ADK expression as a biomarker. These 
include PEL, MM, and plasmablastic lymphoma patients, but pos-
sibly other hematological malignancies. Additionally, the emerg-
ing scenario of ADK expression in other cancer subtypes suggests 
further promise for this compound in such tumors.
Methods
Electrophoretic mobility shift assays. BC3 or LCL9001 cells were plated 
at 5 × 105 cells/ml, and treated with the hit compounds at 25 μM or with 
NSC39368 at 5, 10, 25, and 50 μM for 24 hours. Nuclear extracts were 
obtained as previously described (53), and EMSAs performed using an 
NF-κB–specific oligonucleotide probe.
Viability assays. Cell viability assays were performed by plating of 
log-phase cells in RPMI complete media with 20% FBS at 1 × 105 cells/
ml, with concentrations of 6-ETI or phospho–6-ETI ranging from 0.1 
nM to 100 μM. ATP content at 24, 48, and 72 hours after treatment was 
measured by the CellTiter-Glo kit (Promega), or by trypan blue assay 
as indicated. The LC50 for 6-ETI in each cell line was determined using 
online half-maximal effective concentration (EC50) software from 
Chang Bioscience (changbioscience.com) or using GraphPad Prism 
to determine the LC50 for 6-ETI, phospho–6-ETI, and nucleoside ana-
logs in MM cell lines and primary MM patient samples.
Cell cycle and cell death assays. Assessment of cell death in cell lines 
and primary cells is described in the Supplemental Methods.
DNA synthesis assays. EdU Click-IT assay was used to assess the 
effects of 6-ETI on DNA synthesis, using BC3 and U266 cells (see 
Supplemental Methods).
Immunoblotting. For all intracellular signaling studies, cell lines were 
plated at 2 × 105 cells/ml or at indicated densities in RPMI-1640 with 
20% FBS, and treated with the stated concentrations of 6-ETI, from 6 to 
48 hours. Immunoblotting was performed using the following antibod-
ies: PARP (BD Pharmingen, 556494), LC3B (Cell Signaling Technology, 
2775S), phospho–histone H2AX.X S139 (Cell Signaling Technology, 
2577S), GAPDH (Gene Tex, GTX100118), ADK (Santa Cruz Biotech-
nology, sc-365470), vCyclin (Abcam, ab12208), LANA (Advanced Bio-
technologies, 13-210-100), β-actin (Sigma, A5316), p65 (Cell Signaling 
Technology, C22B4), p50 (Cell Signaling Technology, 3035), Oct-1 (Cell 
Signaling Technology, 4428), pIκBα (Santa Cruz Biotechnology, B-9 
sc-8404), IκBα (Santa Cruz Biotechnology, C-21 sc-371), pIKKα/β (ser 
176) (Santa Cruz Biotechnology, sc-21661), IKKα (Santa Cruz Biotech-
nology, H-744 sc-7218); vFLIP 6/14 antibody was a gift from Mary Col-
lins, University College of London (London, United Kingdom).
Generation of 6-ETI–resistant cell lines. To generate 6-ETI–resistant 
clones, BC3 cells were plated in RPMI-1640 with 50 μg/ml gentamicin 
and 20% FBS under 6-ETI selection in multiple 96-well plates at 1 × 105 
cells/ml. Selection was begun at 15 nM, 30 nM, or 60 nM 6-ETI. Cells 
were split every 3 days, with the dose of 6-ETI doubled at least 1 time 
FDA approved. In fact, among some of the most common purine 
analogs that are used clinically, none compared to 6-ETI in terms 
of their selectivity profile. ADK overexpression has also been found 
in colorectal cancer (49) and astrocytic tumors (50), with ADK 
gene dysregulation in cancer now emerging as a general theme, 
and thus, this compound may prove to be effective across a broad 
range of malignancies. Consequently, ADK expression levels may 
prove to be an important biomarker for drug response in the future.
While the mechanisms of PNA drug action are fairly univer-
sal, many of the newer drugs have been found to possess unique 
additional properties that may confer greater specificity and phar-
macological properties in the clinical context. In fact, even small 
changes in structure are correlated with different active forms (for 
example, some do not require phosphorylation), metabolic proper-
ties, and mechanisms of action, such as resistance to inhibition by 
cellular adenosine deaminase (51). A suggestion that 6-ETI may 
possess a unique mechanism of action arises from our observa-
tion that, in contrast to the established mode of PNA-induced cell 
death, i.e., triggering of the apoptotic cascade, a major mechanism 
of cell death upon treatment was necrosis. Additionally, while 
many ADK-dependent nucleoside analogs can also be activated 
by other cellular kinases, the lack of mutations in other kinase 
genes found by SNP calling in our resistant clones suggests that 
ADK may indeed serve as the primary kinase for 6-ETI activation. 
This notion is supported by increased activity of phospho–6-ETI 
in a cell line with low levels of ADK.
This study led to the discovery of a new nucleoside analog that 
is promising for the treatment of plasmacytic aggressive cancers. 
The survival advantage conferred by 6-ETI in the xenograft mouse 
models was robust (Figures 3 and 7), indicating that 6-ETI treatment 
is effective in inhibiting tumor growth. These results, coupled with 
the therapeutically relevant LC50s of inhibition observed when PEL 
and MM cells were treated with this compound, suggest clear-cut 
promise for further preclinical development. While there is a reason-
able arsenal of drugs for the treatment of MM, resistance to these 
frequently emerges. In addition, plasmablastic lymphoma is a rare 
but highly aggressive malignancy for which no effective treatment is 
available, and the median survival is under 1 year. While ubiquitous 
expression of ADK is expected based on its important metabolic role, 
this is not clearly documented, and at least by immunohistochemis-
try of tonsils, ADK is undetectable in most cells. This may explain 
the lack of toxicity seen in our mouse models. While a complete toxi-
cological analysis is required, National Cancer Institute assay results 
from prior testing of this compound revealed it had been shown to 
exhibit minimal toxicity in other mouse models; it was moderately 
effective in 1 leukemia model (L1210) but not in other leukemia, ade-
nocarcinoma, or melanoma mouse models. While the basic function 
of ADK is known, there is not much mechanistic information about 
its role in cancer, and further biological studies are required. For 
example, there are nuclear and cytoplasmic isoforms (52), but the 
specific functional role of these in different cellular compartments 
is not clear. Mechanistic studies assessing the functional role of ADK 
in specific cellular compartments are ongoing, and should shed light 
on the scope of tumors that may respond to 6-ETI.
In this study, we demonstrated the feasibility of identifying 
a specific inhibitor for herpesvirus-induced tumors and other 
plasma cell malignancies, including plasmablastic lymphoma, 
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formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). Flow was set to 0.3 ml/min, and a gradient of 5% to 95% 
solvent B was applied over a period of 3 minutes. Total run time was 
4 minutes. Eluents were detected using a PDA at a wavelength of 254 
nm. Mass data were obtained in both positive and negative electro-
spray mode, at a cone voltage of 30 V.
In vivo xenograft models. The BC3 in vivo xenograft model was 
set up as previously described (6). Essentially, approximately 4- 
to 6-week-old male NOD/SCID mice (Jackson Laboratory, stock 
001303) were injected i.p. with 1 × 107 BC3NFRen-luc#3 cells and fol-
lowed by in vivo imaging every 3 days. After imaging on day 5 to con-
firm establishment of the tumor, the mice were randomized to vehicle, 
low-dose, and high-dose cohorts, with average tumor burden distrib-
uted evenly across the groups. Each dose cohort contained 10 mice. 
Mice were treated for 9 days beginning at randomization with vehicle 
(PBS–Tween-80), low-dose 6-ETI (150 mg/kg/d), or high-dose 6-ETI 
(300 mg/kg/d). We monitored mice for tumor growth by live imaging 
and weighing, with the sacrifice point determined to be a net gain or 
loss of 10% body weight over a week. Upon reappearance of refractory 
tumors, mice were retreated for a further 9-day interval, and followed 
for a total of 100 days. We assessed compound effects on overall sur-
vival, progression-free survival, and tumor burden by Kaplan-Meier 
curves generated using GraphPad Prism software, and determined 
P values by 2-tailed analysis with log-rank tests.
For the disseminated MM xenograft model, CAG cells were pro-
vided by the Malcolm Moore laboratory at Memorial Sloan Ketter-
ing Cancer Center. 1 × 107 CAG cells stably expressing the HSV-TK-
eGFP-luciferase fusion protein were injected i.v. into NOD/SCID mice 
(NOD/LTSZPrko/J, Jackson Laboratory, stock 001303). Eight days 
after tumor induction, mice were randomized into control and treated 
cohorts and treated i.p. with either PBS–0.05% Tween-80 (vehicle) or 
200 mg/kg of 6-ETI daily for 9 days. Tumor mass or bioluminescence 
(photons/s/cm2/steradian) was evaluated by imaging of the mice 
using an IVIS Imaging system. Statistical analysis was done using a 
2-tailed, unpaired Student’s t test with GraphPad prism.
Statistics. In all cases in which 2 groups were compared, unpaired 
2-tailed Student’s t tests or log-rank tests were used to determine sig-
nificance. A P value less than 0.05 was considered statistically signifi-
cant. All bar and line graphs show mean ± SEM of 3 experiments.
Study approval. These studies were approved by the Weill Cornell 
Medical College IACUC.
Author contributions
UN and JS designed and executed most experiments and cowrote 
the paper. DHH, GA, and JT performed additional experiments. 
JR performed single-nucleotide variant and gene expression 
analysis on RNA-Seq data. HZ performed pathway analysis on 
gene expression data. MAS modeled ADK binding; PJB synthe-
sized 6-ETI and performed HPLC/MS. IG assisted with growth 
curves on cells. DJ and RN processed and provided the primary 
MM patient specimens. DH analyzed preliminary gene expression 
data. YL performed immunohistochemistry on primary tumors 
and IBL1 xenografts. SS and RHS supervised, designed, and exe-
cuted high-throughput screening. JDW designed and supervised 
6-ETI and p6-ETI synthesis and HPLC/MS. OE supervised single- 
nucleotide variant and gene expression analysis. KMK super-
vised some experiments and edited the paper. EC supervised and 
per week. Selection continued until a few clonal populations remained, 
after which the clones were expanded into fresh plates under selection 
with 10 μM 6-ETI. Clones retrieved were designated NSCE-1, NSCE-2, 
NSCE-3, NSCE-4, NSCE-5, NSCE-6, NSCE-7, NSCE-8, in chronologi-
cal order of selection from the original plates. NSCE-4 and NSCE-5 
ceased growth and were not included in the final analysis.
Additionally, in 2 mice in the low-dose cohort of the xenograft 
trial (see below), tumors grew out beyond the 100-day trial cessation 
time point. The ascites from these mice were harvested ex vivo and, 
following Ficoll extraction, placed in culture in RPMI-1640 with 10% 
FBS. After 6-ETI viability assays determined these xenograft cell lines, 
designated 2-3low and 3-5low, to have decreased sensitivity to 6-ETI, 
they were placed under bulk selection in RPMI-1640 with 20% FBS 
and 10 μM 6-ETI to generate resistance. Retesting determined the 
outgrowing cells to be completely resistant to 6-ETI (LC50s >100 μM), 
and these were subsequently included in RNA-Seq analysis.
RNA sequencing. RNA was extracted using the RNeasy Mini Kit 
(Qiagen). Illumina libraries were constructed from RNA with the Illu-
mina Truseq Total RNA Library Preparation Kit (v2) and sequenced 
on Illumina HiSeq in single-end 51-bp mode. Raw data contained 50 
million to 64 million reads, or a total of 2,600–3,300 gigabases, per 
sample. The methods used to analyze the RNA sequencing data are 
provided as Supplemental Methods. RNA-Seq data are available in the 
NCBI’s BioProject database under accession number PRJNA362820.
Computational approach to 3D modeling of ADK WT and mutant 
proteins (G239E and G243K). The x-ray crystallographic structure of 
human adenosine kinase (ADK) (1BX4) was used as the initial struc-
ture with 2 adenosine molecules, one bound to its substrate-binding 
site and the other to its ATP-binding site (38). To prepare the WT 
enzyme model, Protein Preparation Wizard (Schrödinger) (54) was 
used for the addition of missing residues and atoms, removal of the 
adenosine molecule in the ATP-binding site, removal of bad contacts, 
optimization of bond lengths, and removal of all ions and water mol-
ecules. The structure was further optimized by the addition of hydro-
gen atoms using Schrödinger’s Maestro interface. The prepared model 
was then used to generate 2 mutant structures, G239E and G243K, 
using Maestro. The adenosine molecule in the substrate-binding site 
was modified using Maestro to resemble 6-ETI. Six models of ADK 
were prepared to illustrate the positioning of the mutated residues 
with respect to either the bound adenosine or 6-ETI molecules.
In vitro kinase assay. The ADK kinase assay kit was purchased from 
Novocib, France. ADK and ATP provided in the kit were premixed 
into provided kinase assay buffer. The reaction at 37°C was started by 
addition of 6-ETI in DMSO at t = 0, followed by quenching of 10 μl 
of the reaction by 30 μl acetonitrile in an Eppendorf tube at 5, 10, 15, 
30, 60, 120, 150, 180, and 360 minutes. The quenched reaction was 
briefly vortexed and centrifuged at approximately 7,000 g, and then 
the supernatant was transferred into a fresh tube and stored at 4°C for 
HPLC/MS analysis. A control reaction was set up containing ADK, 
ATP, and inosine, in order to generate a standard peak for IMP, while 
ADK, DTT, and ATP controls were generated by dissolving of individ-
ual kit components in a 3:1 acetonitrile/dH2O solution.
HPLC/MS analysis for 6-ETI phosphorylation by ADK. LC/MS 
separations were performed using a Waters ACQUITY UPLC system 
equipped with ACQUITY Photodiode Array (PDA), a Waters Micro-
mass SQD 2000 spectrometer, and a Waters ACQUITY BEH C18 col-
umn (1.7 μm, 2.1 × 100 mm). The solvent system consisted of 0.1% 
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